[CLSTR]
< Back to all clusters
[HEALTH] · 3 sources

started · updated

Part of situation: Achondroplasia clinical trial and regulatory developments (3 clusters)

Navepegritide therapy shows efficacy in achondroplasia clinical trials

achondroplasia navepegritide CNP therapy clinical trials growth velocity

Clinical evaluations of navepegritide, a once-weekly TransCon CNP prodrug therapy, show sustained exposure and efficacy in treating achondroplasia. Data from the phase 3 ApproaCH trial indicate improvements in annualized growth velocity, skeletal alignment, and physical function in children with the condition.

Long-term follow-up data suggest continued benefits in lower-extremity alignment, such as improved tibial-femoral angles and mechanical axis deviation. Safety profiles remain favorable, with low rates of injection-site reactions and no clinically significant hypotension reported. While some participants developed antibodies, these did not appear to impact clinical outcomes.

Ongoing clinical research, including studies at institutions like Texas Children's, continues to investigate the long-term safety, tolerability, and efficacy of weekly subcutaneous doses of TransCon CNP in children and adolescents.

Entities

ApproaCH trial · Texas Children's Hospital · TransCon CNP

Sources

Evaluating Long-Acting CNP Therapy in Achondroplasia | HCPLive [www.hcplive.com]
Evaluating Long-Acting CNP Therapy in Achondroplasia [www.consultantlive.com]
A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia | Texas Children's [www.texaschildrens.org]